Is it time for a paradigm shift in understanding embryo selection? by unknown
Gleicher et al. Reproductive Biology and Endocrinology 2015, 13:3
http://www.rbej.com/content/13/1/3DEBATE Open AccessIs it time for a paradigm shift in understanding
embryo selection?
Norbert Gleicher1,2*, Vitaly A Kushnir1 and David H Barad1,2Abstract
Background: Embryo selection has been an integral feature of in vitro fertilization (IVF) almost since its inception.
Since the advent of extended blastocyst stage embryo culture, and especially with increasing popularity of elective
single embryo transfer (eSET), the concept of embryo selection has increasingly become a mainstay of routine IVF.
Discussion: We here, however, argue that embryo selection via blastocyst stage embryo transfer (BSET), as currently
practiced, at best improves IVF outcomes only for a small minority of patients undergoing IVF cycles. For a large
majority BSET is either ineffective or, indeed, may actually be harmful by decreasing IVF pregnancy chances. Overall,
only a small minority of patients, thus, benefit from prolonged embryo culture, while BSET, as a tool to enhance IVF
outcomes, is increasingly utilized as routine care in IVF for all patients.
Summary: Since newer methods of embryo selection, like preimplantation genetic screening (PGS) and closed
system embryo incubation with time-lapse photography are practically dependent on BSET, these concepts of
embryo selection, currently increasingly adopted in mainstream IVF, require reconsideration. They, automatically,
transfer the downsides of BSET, including decreases in IVF pregnancy chances in some patients, to these new
procedures, and in addition raise serious questions about cost-effectiveness.Background
As delivery of a single healthy child is increasingly per-
ceived as the only desired outcome for in vitro fertilization
(IVF), the concept of embryo selection (ES) has gained
ever-greater popularity.
ES is not a new concept; it has been an essential part
of IVF practice almost since the inception of IVF. The
search for best embryos (in the past), and the search for
the best single embryo overall (now) in association with
elective single embryo transfer (eSET) has always been a
“holy grail” of IVF. Recent experiences with ES, however,
raise serious questions about the validity of the concept,
as currently proposed and increasingly integrated by
many IVF centers all over the world into routine clinical
IVF practice.
Though already considered before as a concept [1,2],
ES for the first time significantly affected routine IVF with
introduction of blastocyst stage embryo transfer (BSET),
when Schoolcraft’s groups reported that implantation and* Correspondence: ngleicher@thechr.com
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unless otherwise stated.clinical pregnancy rates after BSET appeared superior to
cleavage-stage embryo transfers (CSET) [3,4].
The utilization of BSET has, since, made increasing in-
roads into IVF, as more and more IVF centers switched
from day-3 cleavage stage to routine day-5/6 transfers of
blastocyst-stage embryos. BSET received further support,
when recently an allegedly improved method of preim-
plantation genetic screening (PGS), utilizing trophectoderm
biopsy (an additional, secondary method of ES), was
proposed as part of routine IVF, and quickly found sup-
porters [5,6].
BSET and this new form of PGS are, however, exactly
why the general concept of ES, as discussed below, re-
quires careful reconsideration.Discussion
BSET has to be the starting point for such a discussion.
It is based on the seemingly logical concept that longer
embryo culture in vitro favorably selects best embryos,
while poorer quality embryos will arrest on the way to
culture days-5/6. As before noted, BSET was popularized
by the work of Schoolcraft’s group’s [3,4], but was followedl. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
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ported the concept [7-9].
Despite almost universal acceptance of the hypothesis
that BSET improves pregnancy chances in association with
IVF, available published data suggest that this hypothesis,
at least in part, is actually false. The reason is that BSET
improves pregnancy rates in association with IVF only in
“good-prognosis” patients.
While this statement probably will come as a surprise
to most readers of this debate article, this opinion is
based on rather well supported metaanalyses: In a Cochrane
Database Systemic Review of 18 randomized clinical trials,
comparing CSET and BSET, Blake et al. were the first
to report live birth rates significantly favoring BSET but
only for “good-prognosis” patients [10]. Table 1 summarizes
in detail the findings of this study.
The authors concluded that the study provided evidence
of significant difference in pregnancy and live birth rates
in favor of BSET in “good-prognosis” patients, with high
numbers of 8-cell embryos on day-3 being the most
favored subgroup, and also being the only sub-group
demonstrating no difference in cycle cancellation rates
because of absence of transferrable embryos [10].
Glujovsky et al., five years later in 2012, published an-
other Cochrane metaanalysis on the subject, with results
summarized in Table 2 [11]. They added five studies to
the prior Cochrane review by Blake et al. [10] and, as
Table 2 demonstrates, basically confirmed their prior
conclusions. They, however also added a very important
additional analysis of cumulative pregnancy rates from
single embryo cohorts, obtained during one retrieval, and
either transferred by CSET or BSET.
These authors concluded that, overall, their study pro-
vided evidence of a small but significant difference in live
birth rates favoring BSET. However, cumulative pregnancy
rates from CSETs, including fresh and thaw cycles, sig-
nificantly, and to a substantial degree, exceeded those
of BSETs. They further concluded that this difference,
likely is explained by higher rates of frozen embryos and
lower failures to transfer at least one embryo.
Figure 1 describes schematically the conclusions one has
to reach from these two Cochrane studies: They suggest
that only so-called “good-prognosis” patients really benefit
from BSET. While there is no consensus in the literatureTable 1 Outcome summary of metaanalysis of CSET vs. BSET
Study finding
Improved live birth rate (36.0% vs 29.4%) favoring BSET However, only in goo
randomization on day-3;
Improved embryo freezing rates with CSET
Absence of at least 1 embryo for transfer more frequent with BSET (8.9% vs.
patients there was no such difference**
*18/50 identified trials met randomization (RCT) criteria, and were included.
**Accounts at least partially for BSET’s live births benefits only in “good prognosis”on how “good-prognosis” can or should be defined, Blake
et al. convincingly demonstrated in their analysis that this
means a relatively large number of high quality embryos
on day-3 after fertilization is required for such a definition
[10]. Considering that both studies also suggest that the
number of cancelled cycles and of frozen embryos is pre-
dictive of IVF outcomes [10,11], it would appear reason-
able to assume that a patient with truly “good-prognosis”
should have at least six, but maybe as many as eight, high
quality embryos on day-3.
One has to further conclude that how many embryos
define “good-prognosis,” will change with advancing
female age since implantation rates per embryo decline. In
practical terms this means that, with advancing age, in-
creasingly larger day-3 embryo numbers will be required to
establish a patient’s “good-prognosis” status. Yet, embryo
numbers decline with advancing age.
The ultimate conclusion from all of these considerations,
therefore, has to be that, with reasonable certainty, only
young women with more than 6–8 high quality embryos
on days-3 will benefit from BSET.
But even young women with large embryos numbers
will benefit only if their goal is to achieve pregnancy in
the quickest possible way. If their goal is to maximize
their cumulative pregnancy and delivery chances from
all of their available embryos, then even young women
should only undergo CSETs.
What percentage of “good-prognosis” patients a center
serves will, of course, depend on a center’s patient popu-
lation but also how a given center stimulates patients
since intensity of ovarian stimulation affects available
embryo numbers on day-3. How many “good-prognosis”
women will favor rapid conception over best cumula-
tive outcome chances may also vary between centers,
and will, likely, depend on the quality of the informed
consent.
Combined, the two studies by Blake at al [10] and
Glujovsky et al. [11], therefore suggests that women with
average prognosis, likely will not benefit from BSET, and
only a relative small minority of IVF patients will really
benefit from BSET. Moreover, especially “poor-prognosis”
patients, usually characterized by low functional ovarian
reserve (LFOR), run a significant risk of being harmed by
BSET since they are at highest risk with prolonged embryoby Blake et al. [10]*
OR 95% CI
d prognosis patients, and only when 1.35 1.05 to 1.74
0.45 0.36 to 0.56
2.8% of cycles), though in good prognosis 2.85 1.97 to 4.11
patients.
Table 2 Outcome summary of metaanalysis of CSET vs. BSET by Glujovsky et al. [11]*
Study finding OR 95% CI
12 RCTs (1550 women) significantly higher live births favoring BSET of 38.8% vs. 31.0% 1.40 1.13 to 1.74
Clinical pregnancy rates, however, did not differ (41.6% vs. 38.6%) 1.74 0.99 to 1.32
No difference in miscarriage rates 1.18 0.86 to 1.60
4 RCTs (266 women) significantly improved cumulative pregnancy rates favoring CSET (56.5% vs. 46.3%) 1.58 1.11 to 2.25
11 RCTs (1729 women) rates of embryo freezing significantly higher with CSET 2.28 2.35 to 3.51
16 RCTs (2495 women) absence of at least 1 embryo for transfer was significantly higher with BSET (8.9% vs. 3.34%)** 0.35 0.24 to 0.51
*23/50 identified trials met randomization (RCT) criteria, 5 more than in Blake study [10] and Table 1.
**Accounts at least partially for higher cumulative pregnancy rate with CSET.
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ferrable embryos [11].
All of these conclusions confirm professional opinions,
already previously expressed by some investigators [12,13].
Their opinions and the findings of both Cochrane studies
can only be explained if some cleavage-stage embryos
result in pregnancies and healthy deliveries if transferred
into the uterus on days-3 but fail to survive prolonged
in vitro culture to blastocyst stage, This conclusion contra-
dicts opinions by other investigators that embryos which
do not make it to blastocyst stage also already at cleavage
stage lack pregnancy potential [14,15]. No other possible
scenario, however, explains why cumulative pregnancy
rates from embryos transferred at cleavage stage (day-3)
so significantly outperform transfers at blastocyst stage
(days-5/6) [11].Day 1 Day 2
Figure 1 Schematic scheme, demonstrating increasing pregnancy/del
with lengthening embryo culture. The figure demonstrates with prolong
transfer (white bars), and declining cumulative pregnancy/delivery rates for
loss of potentially viable embryos with normal pregnancy/delivery potentiaIn clinical practice the difference in cumulative preg-
nancy chances between BSET and CSET creates obvious
dilemmas, requiring in some patients choices between bet-
ter immediate or better cumulative pregnancy chances.
This dilemma, however, only exists in IVF cycles with large
embryo numbers, where ES may make sense to maximize
immediate pregnancy chances. One group of patients who
immediately comes to mind is, of course, young women
with polycystic ovary syndrome (PCOS).
Women with LFOR, who usually produce small egg and
embryo numbers, should not be cultured to blastocyst
stage. This, of course, mostly includes older women but
also younger patients with premature ovarian aging (POA).
Current absence of reliable age-specific data as to what
represents “good-prognosis” patients represents a poten-
tial clinical dilemma. Since this definition, as noted before,Day 3 Days 5/6
ivery rates and declining cumulative pregnancy/delivery rates
ed embryo culture increasing pregnancy/delivery rates per embryo
whole embryo cohorts (black bars). This discrepancy, likely, reflects the
l during prolonged embryo culture. For further detail see text.
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appropriate to statistically define “good prognosis” at every
program individually based on embryo numbers on day-3.
As also, noted before, since embryo implantation rates
decline with advancing female age, this number will have
to be age-adjusted.
Cost effectiveness considerations create a second di-
lemma because prolonged embryo culture adds cost to an
already expensive IVF procedure. We have been unable to
find specific data on additional costs from BSET in the
literature; but two days of additional embryo culture, of
course, have to incur significant additional staff, media,
equipment and space costs. Moreover, young women with
normal ovarian reserve and large day-embryo numbers
will, most likely, also achieve excellent pregnancy and
delivery rates with CSET. Whether a small incremental
gain in pregnancy and delivery chances, therefore, in
such patients is cost-effective, also still remains to be
determined.
Even though BSET is gaining increasing acceptance in
routine clinical IVF, both of these very obvious clinical
dilemmas point out that this surge in utilization of ex-
tended embryo culture has been occurring without proper
definition of suitable patient populations. The unavoidable
conclusion, therefore, is that among women currently
undergoing routine BSET, a large majority does so without
gaining clinical benefits, and some even with harm to their
pregnancy chances.
Further considerations of cost-effectiveness of BSET in
good prognosis patients also have to take into account
that BSET is increasingly combined with eSET. Whether
eSET or two-embryo transfer should be routine in IVF,
and at which ages, has in itself, remained a still contro-
versial issue, and exceeds the framework of this manu-
script. All of these issues, however, well demonstrate the
multifactorial nature of a decision-making process that
is required in devising appropriate IVF strategies.
Trisha Greenhalgh, a leading expert on evidence-based
medicine and colleagues form the Evidence Based Medical
Renaissance Group, recently pointed this issue out in
severely criticizing how evidence-based medicine is cur-
rently practiced [16]. We strongly recommend to readers
of this opinion piece to read Greenhalgh’s manuscript in
its entirety. It is really remarkable how much all of those
authors’ criticisms apply to the subject of ES, as currently
practiced in association with IVF, and, addressed here.
Which brings us to PGS, which in its recent reintro-
duction to IVF is performed by utilizing trophectoderm
biopsy of embryos at blastocyst stage. The hypothesis
behind PGS assumes that further ES can be obtained by
selecting out euploid embryos for transfer [7]. By relying on
BSET after trophectoderm biopsy of day-5/6 embryos, PGS,
of course, automatically subjects itself to all of above raised
concerns about BSET. One, therefore, has to concludethat PGS should only be considered in “good-prognosis”
patients [17].
Because the additional cost of PGS is far in excess to
that of prolonged embryo culture, above noted two clinical
dilemmas apply to PGS to an even more significant de-
gree. The cost-effectiveness of BSET in association with
PGS in “good-prognosis” patients is, therefore, even more
questionable than with BSET alone. Potentially troubling
further doubts about PGS as a method of ES were recently
raised by Casper’s group in Toronto, who questioned
the reproducibility of trophectoderm biopsy results in an
ESHRE presentation, which attracted considerable atten-
tion [18].
Finally, these questions about ES also raise doubts
about recently marketed automated closed embryo culture
and time-lapse photography systems, claiming ES benefits.
The primary claim of these systems is that they maximize
embryo selection and subsequent BSET. A recently pub-
lished comprehensive review of the literature concluded
that these platforms have the potential of revolutionizing
embryology; but the authors also concluded that currently
available data have so far failed to demonstrate outcome
benefits [19].
Following publication of this review, a first randomized
study of such a system reported mild outcome benefits for
the system. Importantly, the authors, however, acknowl-
edged that their conclusions (again) were only applicable
to very “good- prognosis” patients [20]. Despite marginal
outcome improvements in “good-prognosis” patients, this
study, therefore, again raises questions about utility of
ET in only a relatively small group of “good-prognosis” pa-
tients, and about cost-effectiveness, especially considering
that costs of currently marketed automated embryo cul-
ture systems in the U.S. exceed $100,000.
Summary
All of these considerations create significant concern about
the rapidly and uncontrolled utilization of ES in routine
IVF. Our concern is particularly directed at the fact that
patients are asked to pay for ES, while a majority among
them, likely, will either gain no outcome benefits or actu-
ally face reduced pregnancy chances.
Considering that in 2012 (the last year national data
are available for) in the U.S. alone almost 200,000 IVF
cycles were performed, and worldwide approximately
1.5 million, the ethical and economic dimensions of
here outlined problems appear obvious.
Particularly troublesome is the indiscriminate applica-
tion of ES in women of all ages, and independent of FOR,
when treatment decisions really should be individualized,
based on the best benefits for patients [16]. Currently
utilized methods of ES, at minimum, therefore need to
be carefully reevaluated under objective study conditions,
considering patients’ ages and their degree of LFOR.
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embryo markers, denoting superior embryo quality and
pregnancy chances, should be abandoned. Being able to
identify embryos with maximal implantation and preg-
nancy chances, still, represents a “holy grail” of IVF, espe-
cially if such markers can be clinically utilized in cost
effective ways. The concepts of ES so far pursued in IVF
practice, however, do not appear to work efficiently.
In practical terms this means that the clinical utilization
of current ES methods should be restricted to investiga-
tional use until target patient populations are identified
in which ES really does offer clinical outcome benefits.
Moreover, new ideas about how ES could be achieved
cost-effectively appear urgently needed.
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